NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

TSX · Drug Manufacturers - Specialty & Generic · CAD

Apotex Health Corp. (APTX.TO) Stock Analysis

Apotex Health Corp. (APTX.TO) is a Drug Manufacturers - Specialty & Generic stock listed on TSX and quoted in Canadian Dollar.

Last Updated: October 21, 2026

APTX.TO

CA$33.23

+CA$0.73 (+2.25%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare APTX.TO with… →

APTX.TO Key Statistics

As of Oct 21, 2026
Trading
Open
CA$32.61
Previous Close
CA$32.50
Day's Range
32.59–33.31
52-Week Range
26.05–40.18
Volume
249.84K
Valuation
Market Cap
CA$7.59B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
14.09
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.38
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.14
Financials (FY)
Revenue (FY)
CA$3.49B+4.21%
Net Income (FY)
CA$373.78M+146.39%
Profit marginThe share of revenue left as profit after all costs and taxes.
−0.85%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
228.50M
Dividend and dates
Dividend
CA$0.06+0.18%
Ex-Dividend Date
September 15, 2026
Earnings Date
November 12, 2026
Avg Volume
493.17K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

Apotex Health Corp. (APTX.TO) has a market capitalization of CA$7.59B.

In fiscal 2025, APTX.TO reported revenue of CA$3.49B.

APTX.TO Revenue and Earnings by Fiscal Year

FY ends March
Fiscal yearRevenueNet incomeNet margin
2025CA$3.49BCA$373.78M10.7%
2024CA$3.35BCA$151.70M4.5%
2023CA$2.94B−CA$146.92M−5.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$3.49BCA$1.94BCA$1.04BCA$373.78M10.7%
2024CA$3.35BCA$1.79BCA$765.76MCA$151.70M4.5%
2023CA$2.94BCA$1.10BCA$194.19M−CA$146.92M−5.0%

Annual figures as reported, in the company's reporting currency. As of March 31, 2026.

APTX.TO Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricAPTX.TODrug Manufacturers - Specialty & Generic medianvs median
P/S ratio2.382.1013% above
Profit margin−0.85%−8.14%7.3 pts above

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

The market values Apotex Health Corp. (APTX.TO) at CA$7.59B. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 6,000 employees.

The most recent close on file for APTX.TO is CA$33.23, dated October 21, 2026. That is +CA$0.73 (+2.25%) against the previous close. The 52-week range on file runs from CA$26.05 to CA$40.18. The latest close sits 27.56% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to CA$3.49B. That is +4.21% against the prior fiscal year, when revenue was CA$3.35B. The same year closed with net income of CA$373.78M. That is +146.39% against the prior fiscal year. The reported profit margin is −0.85%. That is 7.3 percentage points above the Drug Manufacturers - Specialty & Generic median of −8.14%. Trailing earnings per share are −0.14.

Across the 3 fiscal years on file, revenue moves from CA$2.94B in 2023 to CA$3.49B in 2025. Of those 3 years, 2 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. On forward earnings the ratio is 14.09. Measured against sales, the shares trade at 2.38 times revenue. On price-to-sales that is 13.12% above the Drug Manufacturers - Specialty & Generic median of 2.1. 97 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

Growth & Income

Shareholders receive a dividend, yielding 0.18% on the latest price. That is 2 percentage points below the Drug Manufacturers - Specialty & Generic median yield of 2.17%. At the indicated rate that is CA$0.06 a share a year. The ex-dividend date on file is September 15, 2026.

So far in 2026 the total return is +23.07%.

Peer Comparison

Apotex Health Corp. (APTX.TO) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Apotex Health Corp. APTX.TO CA$7.59B —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

Market caps are shown in each company's own trading currency, without conversion, and the peers are listed in order of these unconverted figures.

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Apotex Health Corp. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Apotex Health Corp.

Apotex Health Corp. operates as a pharmaceutical manufacturing company in Canada, the United States, Mexico, and India. The company develops, manufactures, and distributes a portfolio of prescription and generic pharmaceuticals, oncology biosimilar pharmaceuticals, branded specialty pharmaceuticals, and branded consumer health and wellness products. Apotex Health Corp. has a strategic partnership with Halo Pharmaceutical, Inc. The company was formerly known as Artemis Parent, Inc. and changed its name to Apotex Health Corp. in May 2026. The company was founded in 1974 and is headquartered in Toronto, Canada. Apotex Health Corp. operates as a subsidiary of SK Artemis Holdings, II, LLC.

Visit website →